• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

格雷夫斯病的药物治疗管理方面

Management Aspects of Medical Therapy in Graves Disease.

作者信息

Shah Rutu, Adamson Samantha E, Jasim Sina

机构信息

Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri.

Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri.

出版信息

Endocr Pract. 2025 Apr;31(4):536-546. doi: 10.1016/j.eprac.2024.12.012. Epub 2024 Dec 17.

DOI:10.1016/j.eprac.2024.12.012
PMID:39701285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12005956/
Abstract

OBJECTIVE

Graves disease (GD) is the most common cause of hyperthyroidism. Treatment options include antithyroid drugs (ATDs), radioactive iodine, and surgery. In this review, we focus on the medical aspects of managing GD.

METHODS

The authors conducted a literature review of PubMed to include studies and review articles on GD management, ATDs, long-term safety of antithyroid drugs, hyperthyroidism in pregnancy, Graves ophthalmopathy, and special circumstances related to hyperthyroidism.

RESULTS

In adjunction to ATDs, medical management for GD also includes beta-blockers, glucocorticoids, and iodine containing agents. ATDs are currently the preferred option for initial management of GD, reflecting a shift in practice observed in the United States over the past 2 decades. ATDs in appropriate doses are well-tolerated and safe when used for longer duration, during pregnancy, and other circumstances discussed in this article. Routine thyroid function tests are important for monitoring. Thyrotropin receptor antibody plays an essential role in determining duration of treatment and assessing the likelihood of recurrence.

CONCLUSION

Medical management of GD with antithyroid drug is safe and effective. Long-term use beyond 24 months in patients with elevated thyrotropin receptor antibody is a reasonable alternative option to surgery and radioactive iodine due to higher rates of remission.

摘要

目的

格雷夫斯病(GD)是甲状腺功能亢进最常见的病因。治疗选择包括抗甲状腺药物(ATD)、放射性碘和手术。在本综述中,我们聚焦于GD管理的医学方面。

方法

作者对PubMed进行了文献综述,纳入关于GD管理、ATD、抗甲状腺药物的长期安全性、妊娠甲亢、格雷夫斯眼病以及与甲亢相关特殊情况的研究和综述文章。

结果

除ATD外,GD的药物管理还包括β受体阻滞剂、糖皮质激素和含碘制剂。ATD目前是GD初始管理的首选,反映了过去20年在美国观察到的实践转变。适当剂量的ATD在长期使用、妊娠及本文讨论的其他情况下耐受性良好且安全。常规甲状腺功能检查对监测很重要。促甲状腺素受体抗体在确定治疗时长和评估复发可能性方面起关键作用。

结论

使用抗甲状腺药物对GD进行药物管理安全有效。对于促甲状腺素受体抗体升高的患者,超过24个月的长期使用因缓解率较高,是手术和放射性碘之外合理的替代选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2b/12005956/58ef5b857fb6/nihms-2065645-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2b/12005956/50190bcd43ba/nihms-2065645-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2b/12005956/58ef5b857fb6/nihms-2065645-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2b/12005956/50190bcd43ba/nihms-2065645-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2b/12005956/58ef5b857fb6/nihms-2065645-f0002.jpg

相似文献

1
Management Aspects of Medical Therapy in Graves Disease.格雷夫斯病的药物治疗管理方面
Endocr Pract. 2025 Apr;31(4):536-546. doi: 10.1016/j.eprac.2024.12.012. Epub 2024 Dec 17.
2
A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.2023 年全球 Graves 病管理临床实践模式调查:十年变迁。
J Clin Endocrinol Metab. 2024 Oct 15;109(11):2956-2966. doi: 10.1210/clinem/dgae222.
3
Diagnosis and treatment of Graves disease.格雷夫斯病的诊断与治疗
Ann Pharmacother. 2003 Jul-Aug;37(7-8):1100-9. doi: 10.1345/aph.1C299.
4
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.格雷夫斯甲状腺和甲状腺外疾病的管理:更新。
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
5
Definitive treatment of Graves' disease in children and adolescents.儿童和青少年 Graves 病的确定性治疗。
Endokrynol Pol. 2021;72(6):661-665. doi: 10.5603/EP.a2021.0092. Epub 2021 Dec 2.
6
Management of Graves' hyperthyroidism: present and future.格雷夫斯病甲亢的管理:现状与未来。
Expert Rev Endocrinol Metab. 2022 Mar;17(2):153-166. doi: 10.1080/17446651.2022.2052044. Epub 2022 Mar 14.
7
Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.格雷夫斯病合并甲状腺眼病的甲状腺功能亢进症治疗
J Clin Endocrinol Metab. 2025 Mar 17;110(4):922-930. doi: 10.1210/clinem/dgaf009.
8
Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.格雷夫斯病甲亢治疗选择的比较有效性:一项历史性队列研究
Thyroid. 2017 Apr;27(4):497-505. doi: 10.1089/thy.2016.0343. Epub 2017 Feb 6.
9
How to manage Graves' disease in women of childbearing potential.如何管理有生育潜力女性的格雷夫斯病。
Clin Endocrinol (Oxf). 2023 May;98(5):643-648. doi: 10.1111/cen.14705. Epub 2022 Mar 8.
10
Treatment of Graves' disease in children: The Portuguese experience.儿童格雷夫斯病的治疗:葡萄牙的经验。
Endocrinol Diabetes Nutr (Engl Ed). 2018 Mar;65(3):143-149. doi: 10.1016/j.endinu.2017.11.014. Epub 2018 Jan 9.

本文引用的文献

1
Evaluation and Management of Thyrotoxicosis During Pregnancy.妊娠期甲状腺毒症的评估与管理。
Endocrinol Metab Clin North Am. 2024 Sep;53(3):349-361. doi: 10.1016/j.ecl.2024.05.002. Epub 2024 Jun 22.
2
US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease.基于美国的自身免疫性甲状腺疾病促甲状腺素受体抗体前瞻性盲法研究。
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1619-e1624. doi: 10.1210/clinem/dgae448.
3
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease.
Graves 病患者长期抗甲状腺药物治疗的处理方法。
J Clin Endocrinol Metab. 2024 Sep 16;109(10):e1881-e1888. doi: 10.1210/clinem/dgae456.
4
Effects of Low-dose Methotrexate With Methimazole in Patients With Graves' Disease: Results of a Randomized Clinical Trial.低剂量甲氨蝶呤联合甲巯咪唑治疗Graves病患者的效果:一项随机临床试验的结果
J Clin Endocrinol Metab. 2025 Jan 21;110(2):489-497. doi: 10.1210/clinem/dgae472.
5
A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.2023 年全球 Graves 病管理临床实践模式调查:十年变迁。
J Clin Endocrinol Metab. 2024 Oct 15;109(11):2956-2966. doi: 10.1210/clinem/dgae222.
6
The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists.需要 GREAT+ 评分来预测格雷夫斯病的复发:一项针对患者和内科专家的问卷调查。
J Endocrinol Invest. 2024 Oct;47(10):2499-2505. doi: 10.1007/s40618-024-02358-7. Epub 2024 Mar 25.
7
Thyroid disorders induced by immune checkpoint inhibitors.免疫检查点抑制剂引起的甲状腺疾病。
Endocrine. 2024 Jul;85(1):67-79. doi: 10.1007/s12020-024-03718-2. Epub 2024 Feb 12.
8
Hyperthyroidism.甲状腺功能亢进症
Lancet. 2024 Feb 24;403(10428):768-780. doi: 10.1016/S0140-6736(23)02016-0. Epub 2024 Jan 23.
9
Statins and thyroid eye disease (TED): a systematic review.他汀类药物与甲状腺眼病(TED):一项系统综述。
Endocrine. 2024 Jul;85(1):11-17. doi: 10.1007/s12020-023-03680-5. Epub 2024 Jan 9.
10
Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model.Graves 甲亢患者短期或长期甲巯咪唑治疗停药时的复发风险:一项随机试验和风险评分模型。
Endocrine. 2024 May;84(2):577-588. doi: 10.1007/s12020-023-03656-5. Epub 2024 Jan 2.